

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRELIMINARY FINANCIAL INFORMATION OF CR BOYA BIO-PHARMACEUTICAL FOR THE YEAR ENDED 31 DECEMBER 2023

On 13 March 2024, CR Boya Bio-pharmaceutical released its unaudited preliminary financial information for the year ended 31 December 2023.

China Resources Boya Bio-pharmaceutical Group Company Limited (華潤博雅生物製藥集團股份有限公司) (“**CR Boya Bio-pharmaceutical**”) is a company incorporated in the People’s Republic of China. The shares of CR Boya Bio-pharmaceutical are listed on the Shenzhen Stock Exchange. As of the date of this announcement, China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) indirectly holds approximately 29.28% of the total share capital and approximately 40.59% voting rights in the total share capital of CR Boya Bio-pharmaceutical, and therefore, CR Boya Bio-pharmaceutical is a subsidiary of the Company.

On 13 March 2024, CR Boya Bio-pharmaceutical released its unaudited preliminary financial information for the year ended 31 December 2023 (the “**reporting period**”) (the “**CR Boya Bio– pharmaceutical Preliminary Financial Information**”). Set out below are the key financial information of the CR Boya Bio-pharmaceutical Preliminary Financial Information:

I. MAJOR FINANCIAL INFORMATION AND INDICATORS FOR THE YEAR OF 2023

Unit: RMB ten thousand

| Item | The reporting period | The corresponding period of previous year | Increase/decrease (%) |
|---|-----------------------------|--|------------------------------|
| Total operating revenue | 265,197.95 | 275,870.13 | -3.87% |
| Operating profit | 35,522.51 | 53,218.07 | -33.25% |
| Total profit | 35,371.18 | 53,200.17 | -33.51% |
| Net profit attributable to the shareholders of the listed company | 23,746.56 | 43,219.76 | -45.06% |
| Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses) | 14,307.57 | 39,212.45 | -63.51% |
| Basic earnings per share (<i>RMB/share</i>) | 0.47 | 0.86 | -45.35% |
| Weighted average return on net asset (%) | 3.28% | 6.18% | -2.9 percentage points |

| Item | As of the end of the reporting period | As of the beginning of the reporting period | Increase/decrease (%) |
|--|---------------------------------------|---|-----------------------|
| Total assets | 782,890.03 | 803,317.54 | -2.54% |
| Equity attributable to the shareholders of the listed company | 731,975.06 | 718,563.45 | 1.87% |
| Share capital (<i>ten thousand shares</i>) | 50,424.87 | 50,424.87 | 0 |
| Net assets per share attributable to the shareholders of the listed company (<i>RMB/share</i>) | 14.52 | 14.25 | 1.89% |

Notes:

1. The above data are presented on a consolidated basis of CR Boya Bio-pharmaceutical.
2. The above indicators, including net profit, basic earnings per share, return on equity, equity attributable to shareholders, and net assets per share, are based on those attributable to the shareholders of CR Boya Bio-pharmaceutical. Basic earnings per share and return on net asset are calculated using weighted average method.

II. DETAILS OF OPERATING RESULTS AND FINANCIAL POSITIONS

(i) The operating performance during the reporting period and the main factors affecting the operating performance

- (1) During the reporting period, CR Boya Bio-pharmaceutical continued to advance and implement the “14th Five-Year Plan” strategic plan, with a management focus on “innovation integration and quality improvement,” specifically targeting the development of the blood products business. In 2023, steady growth was achieved in both the operating revenue and net profit of the blood products business.

- (2) CR Boya Bio-pharmaceutical transferred the equity of Guangdong Fuda Pharmaceutical Co., Ltd. (廣東複大醫藥有限公司) (“**Fuda Pharmaceutical**”), and Guizhou Tianan Pharmaceutical Co., Ltd. (貴州天安藥業股份有限公司) (“**Tianan Pharmaceutical**”) in September 2023 and October 2023, respectively, resolving the competition between it and its controlling shareholder. As Fuda Pharmaceutical and Tianan Pharmaceutical were no longer included in the consolidated financial statements starting from October 2023 and November 2023, respectively, the total operating revenue of CR Boya Bio-pharmaceutical amounted to RMB2,651.9795 million, representing a year-on-year decrease of 3.87%.
- (3) In 2023, CR Boya Bio-pharmaceutical achieved a net profit attributable to shareholders of the listed company of RMB237.4656 million, representing a decrease of 45.06% compared to the same period last year. This was mainly due to the provision for impairment of goodwill in the amount of RMB298.4134 million in relation to the acquisition of Nanjing Xinbai Pharmaceutical Co., Ltd. (南京新百藥業有限公司) (“**Nanjing Xinbai Pharmaceutical**”) as well as other asset impairment provisions. For more details, please refer to the “Announcement of the Company Regarding the Provision for Asset Impairment in 2023” on Jucaiwang, the ChiNext information disclosure website designated by the China Securities Regulatory Commission.

(ii) Explanation of the changes in main financial information

During the reporting period, the total assets of CR Boya Bio-pharmaceutical amounted to RMB7,828.9003 million, representing a decrease of 2.54% compared to the same period last year. This decrease was primarily due to the provision for impairment of goodwill in the amount of RMB298.4134 million in relation to the acquisition of Nanjing Xinbai Pharmaceutical. The owner’s equity attributable to shareholders of the listed company amounted to RMB7,319.7506 million, representing an increase of 1.87% compared to the same period last year. CR Boya Bio-pharmaceutical maintained stable operations and good asset condition.

III. MAIN REASONS OF DIFFERENCE FROM THE PREVIOUS RESULTS ESTIMATE

Prior to the publication of this announcement, the Company did not publish any results estimate for CR Boya Bio-pharmaceutical for the year 2023.

The CR Boya Bio-pharmaceutical Preliminary Financial Information have been prepared in accordance with the PRC Generally Accepted Accounting Principles and are unaudited nor reviewed. The financial information to be disclosed by CR Boya Bio-pharmaceutical in its annual report for the year ended 31 December 2023 shall prevail.

The financial information is limited to CR Boya Bio-pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the final audited financial results of CR Boya Bio-pharmaceutical, please refer to the annual report for the year ended 31 December 2023 to be published by CR Boya Bio-pharmaceutical on the website of the Shenzhen Stock Exchange (www.szse.cn).

By Order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Wuxi, 13 March 2024

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.